These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31384431)

  • 61. Prognostic value of follow-up vasoreactivity test in pulmonary arterial hypertension.
    Ishii S; Hatano M; Maki H; Minatsuki S; Saito A; Yagi H; Shimbo M; Soma K; Numata G; Fujiwara T; Takeda N; Komuro I
    J Cardiol; 2023 Jul; 82(1):69-75. PubMed ID: 36682710
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Nailfold capillaroscopic changes in patients with idiopathic pulmonary arterial hypertension and systemic sclerosis-related pulmonary arterial hypertension.
    Corrado A; Correale M; Mansueto N; Monaco I; Carriero A; Mele A; Colia R; Di Biase M; Cantatore FP
    Microvasc Res; 2017 Nov; 114():46-51. PubMed ID: 28619664
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Biomarkers for Pulmonary Vascular Remodeling in Systemic Sclerosis: A Pathophysiological Approach.
    Odler B; Foris V; Gungl A; Müller V; Hassoun PM; Kwapiszewska G; Olschewski H; Kovacs G
    Front Physiol; 2018; 9():587. PubMed ID: 29971007
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Frequencies of borderline pulmonary hypertension before and after the DETECT algorithm: results from a prospective systemic sclerosis cohort.
    Hoffmann-Vold AM; Fretheim H; Midtvedt Ø; Kilian K; Angelshaug M; Chaudhary A; Gunnarsson R; Brunborg C; Garen T; Andreassen AK; Gude E; Molberg Ø
    Rheumatology (Oxford); 2018 Mar; 57(3):480-487. PubMed ID: 29237073
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
    [No Abstract]   [Full Text] [Related]  

  • 66. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies.
    Le Pavec J; Girgis RE; Lechtzin N; Mathai SC; Launay D; Hummers LK; Zaiman A; Sitbon O; Simonneau G; Humbert M; Hassoun PM
    Arthritis Rheum; 2011 Aug; 63(8):2456-64. PubMed ID: 21538327
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis.
    Cavagna L; Caporali R; Klersy C; Ghio S; Albertini R; Scelsi L; Moratti R; Bonino C; Montecucco C
    J Rheumatol; 2010 Oct; 37(10):2064-70. PubMed ID: 20634241
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).
    Kowal-Bielecka O; Avouac J; Pittrow D; Huscher D; Behrens F; Denton CP; Foeldvari I; Humbert M; Matucci-Cerinic M; Nash P; Opitz CF; Rubin LJ; Seibold JR; Strand V; Furst DE; Distler O;
    J Rheumatol; 2011 Nov; 38(11):2419-27. PubMed ID: 21965635
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Serum uric acid as a risk predictor for erectile dysfunction.
    Salem S; Mehrsai A; Heydari R; Pourmand G
    J Sex Med; 2014 May; 11(5):1118-24. PubMed ID: 24621054
    [TBL] [Abstract][Full Text] [Related]  

  • 70. An Overview of Different Techniques for Improving the Treatment of Pulmonary Hypertension Secondary in Systemic Sclerosis Patients.
    Ruaro B; Salton F; Baratella E; Confalonieri P; Geri P; Pozzan R; Torregiani C; Bulla R; Confalonieri M; Matucci-Cerinic M; Hughes M
    Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328169
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Circulating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary Hypertension.
    Richter MJ; Tiede SL; Sommer N; Schmidt T; Seeger W; Ghofrani HA; Schermuly R; Gall H
    PLoS One; 2016; 11(11):e0165982. PubMed ID: 27802345
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
    Launay D; Humbert M; Berezne A; Cottin V; Allanore Y; Couderc LJ; Bletry O; Yaici A; Hatron PY; Mouthon L; Le Pavec J; Clerson P; Hachulla E
    Chest; 2011 Oct; 140(4):1016-1024. PubMed ID: 21474572
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Is pulmonary arterial hypertension really a late complication of systemic sclerosis?
    Hachulla E; Launay D; Mouthon L; Sitbon O; Berezne A; Guillevin L; Hatron PY; Simonneau G; Clerson P; Humbert M;
    Chest; 2009 Nov; 136(5):1211-1219. PubMed ID: 19429720
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort.
    Mihai C; Antic M; Dobrota R; Bonderman D; Chadha-Boreham H; Coghlan JG; Denton CP; Doelberg M; Grünig E; Khanna D; McLaughlin VV; Müller-Ladner U; Pope JE; Rosenberg DM; Seibold JR; Vonk MC; Distler O
    Ann Rheum Dis; 2018 Jan; 77(1):128-132. PubMed ID: 29061853
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study.
    Thakkar V; Stevens W; Prior D; Rabusa C; Sahhar J; Walker JG; Roddy J; Lester S; Rischmueller M; Zochling J; Nash P; Gabbay E; Youssef P; Proudman SM; Nikpour M
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):129-136. PubMed ID: 27214686
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension.
    Valerio CJ; Schreiber BE; Handler CE; Denton CP; Coghlan JG
    Arthritis Rheum; 2013 Apr; 65(4):1074-84. PubMed ID: 23280155
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study.
    Bernstein EJ; Peterson ER; Sell JL; D'Ovidio F; Arcasoy SM; Bathon JM; Lederer DJ
    Arthritis Rheumatol; 2015 May; 67(5):1314-22. PubMed ID: 25581250
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Relationship between YKL-40 and pulmonary arterial hypertension in systemic sclerosis.
    Furukawa T; Matsui K; Kitano M; Yokoyama Y; Sekiguchi M; Azuma N; Imai Y; Hirota S; Yamanishi K; Sano H
    Mod Rheumatol; 2019 May; 29(3):476-483. PubMed ID: 29788800
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
    Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Interrelations Between Serum Uric Acid, Silent Myocardial Infarction, and Mortality in the General Population.
    Ahmad MI; Dutta A; Anees MA; Soliman EZ
    Am J Cardiol; 2019 Mar; 123(6):882-888. PubMed ID: 30617009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.